Premature Menopause Clinic London

Premature Menopause Clinic London We provide a fully comprehensive clinical service to women with health-related problems and fertilit

Here is an interesting study by Wang et al. from United States which evaluated temporal trends in oestrogen replacement ...
23/08/2026

Here is an interesting study by Wang et al. from United States which evaluated temporal trends in oestrogen replacement therapy utilisation among younger gynaecological cancer survivors.

This was a cross-sectional study using the Merative MarketScan Research Database from January 1, 2013, through December 31, 2021. Study included female patients aged 18–51 years with a diagnosis or history of gynaecological cancer. Annual prevalence of oestrogen replacement therapy use was calculated, and trends over time were assessed using annual percent change (APC).

What was found?
Oestrogen replacement utilisation increased from 10.9% in 2013 to 14.1% in 2021 among all gynaecological cancer survivors (APC 3.41%, 95% CI 2.13–4.71%). Increasing hormone replacement use was observed across all cancer subgroups and age categories during the study period. Ovarian cancer survivors consistently had the greatest prevalence of hormone use, whereas uterine cancer survivors had the lowest prevalence across the study period. Among the age sub-groups, the 18–34 years old age group had the largest increase in hormone utilisation, from 6.8% to 10.5% (APC 5.68%, 95% CI 3.1–8.33) over the study period.

The researchers concluded that hormone replacement utilisation among younger gynaecological cancer survivors increased between 2013 and 2021. However, overall use of hormone replacement among gynaecological cancer survivors remained relatively low.

As hormone use continues to rise in this population, the authors recommend further research to identify patient-, provider-, and system-level factors associated with prescribing and uptake and to evaluate gaps or barriers in menopausal survivorship care.

It is important to note, though, that these findings should be interpreted with caution as clinical factors, such as menopausal status, ovarian function, symptom burden, and contraindications, were not available in the data source.

Nevertheless, these trends are important to note. It has taken massive efforts from individuals, patients, clinicians and charities/campaigners to point out the gaps in menopause care for cancer survivors and they continue to fight for better treatment and care pathways. There is certainly increasing awareness about long-term effects of surgical or medical menopause and the benefits versus risks of HRT in various types of cancers.

Menopause and Cancer CIC have been at the forefront of fighting for a positive change for cancer survivors menopause care experiences. On 18th September, they are holding the world’s first Global Menopause and Cancer Conference.

It’s an opportunity for healthcare professionals from around the world to come together to discuss the questions that don’t yet have perfect answers, explore emerging evidence and help shape the future of menopause after cancer care. It will not be just about HRT or medical treatments but it will focus how we can improve survivor’s quality of life in a holistic way including lifestyle modifications, ready access to advice, and long lasting support.

Please join us if you can 🙏🏻

Register here: https://menopauseandcancer.org/menopause-and-cancer-conference/

Study link -
https://pmc.ncbi.nlm.nih.gov/articles/PMC13476577/

Here is an observational real-world cohort study from Ting-Fang Lu et al. looking at long-term systemic outcomes of post...
21/08/2026

Here is an observational real-world cohort study from Ting-Fang Lu et al. looking at long-term systemic outcomes of postmenopausal hormone replacement therapy by age at menopause.

Women who initiated postmenopausal HRT containing oestrogen and/or progestogen within 1 year after menopause diagnosis were propensity score-matched 1:1 with non-users using baseline demographic, clinical, and laboratory covariates. Primary matching yielded 83 670 matched pairs in women who experienced menopause at age ≤60 years and 12 175 matched pairs in women who experienced menopause at age >60 years. A minimum follow-up period of one decade was guaranteed.

In the overall matched cohort of women experiencing menopause at age ≤60 years - compared with non-users, postmenopausal HRT was associated with lower hazards of type 2 diabetes and cardiovascular disease CVD. Skeletal health was preserved, evidenced by a lower hazard of compression fractures. HRT was associated with lower hazards of breast cancer, colorectal cancer and venous thrombosis VTE. In the primary age-stratified model, the >60-year cohort showed a higher breast cancer hazard.

These findings have major limitations - residual confounding, incomplete socioeconomic and screening data, limited details on HRT formulation, route, dose and duration, unavailable breast cancer subtype information and unavailable exact maximum follow-up duration.

But, the take home message is that the long-term associations of postmenopausal HRT are not ‘one-size-fits-all’ but depend strongly on age at menopause. In this analysis with all its limitations, postmenopausal HRT was associated with lower chances of heart disease, bone fractures, and blood clots. However, its association with breast cancer varied substantially by age. For women who experienced menopause prematurely (under age 40), postmenopausal HRT was associated with a lower breast cancer hazard. By contrast, among women who reached menopause after age 60, initiating postmenopausal HRT was associated with a higher breast cancer hazard.

Here is a study on Menopause Hormone Therapy (MHT/HRT), genetic risk for Alzheimer’s, and cognition from Emily Budden an...
20/08/2026

Here is a study on Menopause Hormone Therapy (MHT/HRT), genetic risk for Alzheimer’s, and cognition from Emily Budden and researchers from Centre for Dementia Studies at the Department of Clinical Neuroscience, Brighton & Sussex Medical School.

Researchers are looking for females in the UK aged 40-60 who are about to start HRT for the first time (but haven’t yet started).
The study involves online questionnaires and memory/thinking activities and a simple inner-cheek swab for genetic analysis.

Taking part will help researchers better understand cognitive health during menopause - an area where much more research is needed.
Study details and the link to take part can be found at: 
https://universityofsussex.eu.qualtrics.com/jfe/form/SV_5hy6eIL5HT0thga

Please support (take part or share with others) this important research 🙏🏻

This year’s world menopause day (18th October) theme from the International Menopause Society is ‘Chronic pain at Midlif...
20/08/2026

This year’s world menopause day (18th October) theme from the International Menopause Society is ‘Chronic pain at Midlife’.

Chronic pain affects a significant number of women during and after the menopause transition but remains underestimated and understudied.
There is a need for better research, clinical care pathways, education, recognition and support.

https://www.imsociety.org/education/world-menopause-day-2026/ -medicine

Thank you ASCAT 2026 for the invite to talk on Fertility, Ovarian Reserve Assessment, and Reproductive Options in women ...
19/08/2026

Thank you ASCAT 2026 for the invite to talk on Fertility, Ovarian Reserve Assessment, and Reproductive Options in women with thalassaemia.
There are unique considerations about hormone treatment for hypogonadotropic hypogonadism as well as testing for ovarian reserve and discussing fertility treatment options for women with thalassaemia. Looking forward to the session and learning more and networking on the day.
At UCLH, I am lucky to be working with an excellent haematology team who are proactively involved in multidisciplinary care for thalasaemia patients.

This is the 21st Annual Sickle Cell & Thalassaemia Conference, delivered in continued collaboration with the European Hematology Association (EHA). Academy for Sickle Cell and Thalassaemia (ASCAT) 2026 marks the first chapter of new multi-year conference series, Haemoglobinopathies Without Borders, beginning with Building Care That Lasts: Sustainability in Haemoglobinopathy Care.

https://ascatconferences.com

A wonderful paper from Riley Bove & Ruth Dobson on - ‘Menopause and neurological disorders: a roadmap for research’.Meno...
17/08/2026

A wonderful paper from Riley Bove & Ruth Dobson on - ‘Menopause and neurological disorders: a roadmap for research’.

Menopause and neurology are intertwined in many more ways than we currently understand. In this Roadmap, the authors highlight the historical and scientific challenges that have limited research into the menopause and neurological disease, and set out specific directions for the research needed.

For me, the most interesting section was on brain health after anti-oestrogen treatments such as those for breast cancer.
The authors suggest that studies that have evaluated cognitive outcomes according to type of anti-oestrogen therapy have produced inconsistent results and that there is a clear need for longitudinal analyses of the effects of each anti-oestrogen approach on immediate and long-term cognitive function.

A big thank you to the authors for such a comprehensive document.
https://www.nature.com/articles/s41582-026-01244-5

Multidisciplinary care is a vital part of management of menopause after cancer. Clear and timely communication between o...
14/08/2026

Multidisciplinary care is a vital part of management of menopause after cancer. Clear and timely communication between oncologists, gynaecologists, endocrinologists, psychologists, and allied health professionals can make a huge positive difference to quality of care provided and optimisation of long-term health.

We have been having our monthly menopause after Gynaecology/Breast cancer MDT meetings for a while at UCLH and they have been such a good learning experience for all. We have been able to discuss complex cases to arrive at joint decisions on HRT and non-HRT interventions as well as other aspects of patient care way ahead of them having to wait long for a menopause clinic referral.
Thank you 🙏🏻 Shibani Nicum and Gabriella Yongue for all the work of setting up these monthly MDTs.

Here is a position paper from the FIGO Committee in Women of Menopausal Age on Menopausal hormone therapy and comprehensive postmenopausal care in gynecologic cancer survivors that emphasises multidisciplinary care.
https://obgyn.onlinelibrary.wiley.com/doi/full/10.1002/ijgo.71188

We have often had women in the menopause clinic suffering from burning mouth syndrome or others experiencing altered tas...
13/08/2026

We have often had women in the menopause clinic suffering from burning mouth syndrome or others experiencing altered taste perception during menopause transition.

What do we know about this? Here is a very helpful narrative review from Andrea Butera et al. focussing on menopause and oral health.

Menopause does appear to act as an important systemic modifier of oral health through multifactorial biological mechanisms.

Hormonal changes of menopause can influence oral tissues through complex interactions involving immune regulation, salivary function, bone metabolism, microbial ecology, and behavioral factors.

The authors conclude that increased awareness among dental and medical professionals and a multidisciplinary approach could improve the prevention, diagnosis, and management of oral diseases in postmenopausal women. Much more future research is required on the topic and to better define the role of HRT in this situation.

https://www.mdpi.com/2077-0383/15/15/5757

Thank you Shahara Aziz Ellahi, Jessica Wibisono, and Prof Aimee Spector for this important piece of work. British South ...
12/08/2026

Thank you Shahara Aziz Ellahi, Jessica Wibisono, and Prof Aimee Spector for this important piece of work.
British South Asian women’s menopause experiences are shaped by intersecting cultural, relational, and healthcare factors. Improving culturally sensitive communication, menopause literacy, and inclusive, community-based support may help reduce inequities in menopause care and enhance engagement with services.

Link https://journals.sagepub.com/doi/10.1177/17455057261478338

Address

10 Harley Street
London
W1G9PF

Telephone

+442074678373

Website

Alerts

Be the first to know and let us send you an email when Premature Menopause Clinic London posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Premature Menopause Clinic London:

Shortcuts

Featured

Share

Category